Gamunex (Talecris Biotherapeutics): Full Drug Profile
- Gamunex (Talecris Biotherapeutics) – general information
- Pharmacology of Gamunex (Talecris Biotherapeutics)
- Gamunex (Talecris Biotherapeutics) for patients
- Gamunex (Talecris Biotherapeutics) interactions
- Gamunex (Talecris Biotherapeutics) contraindications
- Additional information about Gamunex (Talecris Biotherapeutics)
Gamunex (Talecris Biotherapeutics) - General Information
Mixture of IgG1 and other antibodies derived from human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. Flebogamma contains the IgG antibody specificities found in the general human population. IgG subclasses are fully represented in the following proportions: IgG1 is 70.3%, IgG2, 24.7%, IgG3, 3.1%, and IgG4,
1.9%
Pharmacology of Gamunex (Talecris Biotherapeutics)
Used as a replacement therapy in inherited humoral immunodeficiency disorders such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich Syndrome. The immune globulins target, bind and kill bacterial cells as well as viral particles. IgG is the monomeric immunoglobulin of which there are four subclasses (IgG1, IgG2, IgG3 and IgG4) in differing abundances (66%, 23%, 7% and 4%). IgAs represent about 15% of the immunoglobulins in the blood. These target inhaled or ingested pathogens.
Gamunex (Talecris Biotherapeutics) for patients
Gamunex (Talecris Biotherapeutics) Interactions
Gamunex (Talecris Biotherapeutics) Contraindications
BayGam should not be given to persons with isolated immunoglobulin A (IgA) deficiency. Such persons have the potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA. 9
BayGam should not be administered to patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
Additional information about Gamunex (Talecris Biotherapeutics)
- Gamunex (Talecris Biotherapeutics) Indication
For treatment of immunodeficiencies, thrombocytopenic purpura, Kawasaki disease, gammablobulinemia, leukemia, bone transplant
- Mechanism Of Action
- Antibodies prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage “tagging” or neutralization (via binding) of pathogen toxins.
- Generic Name
- Immune globulin
- Synonyms
- Ig alpha-2 chain C region
- Drug Category
- Anti-Infectives; Immunomodulatory Agents
- Drug Type
- Biotech; Approved; Investigational
- Other Brand Names containing Immune globulin
- Flebogamma (Instituto Grifols SA); Gamunex (Talecris Biotherapeutics);
- Half Life
- >20 hours (mammalian reticulocytes, in vitro).
- Dosage Forms of Gamunex (Talecris Biotherapeutics)
- Solution Intramuscular
- Chemical IUPAC Name
- Human antibodies
- Chemical Formula
- C6332H9826N1692O1980S42
- Organisms Affected
- Humans and other mammals; Bacteria and protozoa; Various viruses
